Rituximab as Successful Adjunct Treatment in a Patient With Disseminated Nontuberculous Mycobacterial Infection Due to Acquired Anti-Interferon- Autoantibody | Zendy

Christopher A. Czaja | Zendy; Patricia Merkel | Zendy; Edward D. Chan | Zendy; Laurel Lenz | Zendy; M. Wolf | Zendy; R. Alam | Zendy; Stanley Frankel | Zendy; Aryeh Fischer | Zendy; S. Gogate | Zendy; Carlos M. PérezVélez | Zendy; Ver Knight | Zendy

Open Access

Rituximab as Successful Adjunct Treatment in a Patient With Disseminated Nontuberculous Mycobacterial Infection Due to Acquired Anti-Interferon- Autoantibody

Author(s) -

Christopher A. Czaja,

Patricia Merkel,

Edward D. Chan,

Laurel Lenz,

M. Wolf,

R. Alam,

Stanley Frankel,

Aryeh Fischer,

S. Gogate,

Carlos M. PérezVélez,

Ver Knight

Publication year - 2013

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cit809

Subject(s) - medicine , rituximab , autoantibody , nontuberculous mycobacteria , immunology , antimycobacterial , refractory (planetary science) , antibody , tuberculosis , mycobacterium , pathology , mycobacterium tuberculosis , physics , astrobiology

An acquired immune deficiency due to interferon gamma (IFN-γ) autoantibodies was diagnosed in a 78-year-old Japanese man with treatment-refractory disseminated nontuberculous mycobacterial infection. In addition to standard antimycobacterial therapy, he was successfully treated with rituximab to eliminate B cells and thereby the autoantibody. Subsequently, he obtained a sustained remission from infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research